D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, et al: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008, 371 (9613): 660-667. 10.1016/S0140-6736(08)60304-9.
Article
PubMed
Google Scholar
Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, et al: Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology. 2009, 137 (4): 1250-60. 10.1053/j.gastro.2009.06.061.
Article
CAS
PubMed
Google Scholar
Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE: Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009, 136 (2): 441-450. 10.1053/j.gastro.2008.10.051. e441; quiz 716
Article
CAS
PubMed
Google Scholar
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, et al: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007, 132 (1): 52-65. 10.1053/j.gastro.2006.11.041.
Article
CAS
PubMed
Google Scholar
Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, et al: Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008, 135 (5): 1493-1499. 10.1053/j.gastro.2008.07.069.
Article
CAS
PubMed
Google Scholar
Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P: Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008, 103 (12): 3132-3141. 10.1111/j.1572-0241.2008.02175.x.
Article
PubMed
Google Scholar
Coulter A: Partnerships with patients: the pros and cons of shared clinical decision-making. J Health Serv Res Policy. 1997, 2 (2): 112-121.
CAS
PubMed
Google Scholar
Coulter A, Entwistle V, Gilbert D: Sharing decisions with patients: is the information good enough?. BMJ. 1999, 318 (7179): 318-322.
Article
CAS
PubMed
PubMed Central
Google Scholar
Department of Health: The expert patient: a new approach to chronic disease management for the 21st century. 2001, Department of Health, 25216:
Google Scholar
Teutsch C: Patient-doctor communication. Med Clin North Am. 2003, 87 (5): 1115-1145. 10.1016/S0025-7125(03)00066-X.
Article
PubMed
Google Scholar
Hibbard J: Moving toward a more patient-centred health care delivery system. Health Affairs. 2004, VAR 133-VAR135((Suppl Web Exclusive))
Google Scholar
Levinson W, Kao A, Kuby A, Thisted RA: Not all patients want to participate in decision making. A national study of public preferences. J Gen Intern Med. 2005, 20 (6): 531-535. 10.1111/j.1525-1497.2005.04101.x.
Article
PubMed
PubMed Central
Google Scholar
Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA: Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 2002, 24 (4): 552-564. 10.1016/S0149-2918(02)85131-1.
Article
CAS
PubMed
Google Scholar
Johnson M, Guilford S, Libretto SE: Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole. Curr Med Res Opin. 2002, 18 (5): 303-310. 10.1185/030079902125000831.
Article
CAS
PubMed
Google Scholar
Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D: Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial, the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005, 21 (12): 1895-1903. 10.1185/030079905X74862.
Article
CAS
PubMed
Google Scholar
Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ: Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002, 24 (11): 1871-1886. 10.1016/S0149-2918(02)80085-6.
Article
CAS
PubMed
Google Scholar
Kendler D, Kung AW, Fuleihan Gel H, Gonzalez Gonzalez JG, Gaines KA, Verbruggen N, Melton ME: Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004, 48 (3): 243-251. 10.1016/j.maturitas.2003.12.012.
Article
CAS
PubMed
Google Scholar
Weiss M, Vered I, Foldes AJ, Cohen YC, Shamir-Elron Y, Ish-Shalom S: Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res. 2005, 17 (2): 143-149.
Article
CAS
PubMed
Google Scholar
Weiss TW, McHorney CA: Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect. 2007, 10 (3): 211-223. 10.1111/j.1369-7625.2007.00440.x.
Article
PubMed
PubMed Central
Google Scholar
Olden K, DeGarmo RG, Jhingran P, Bagby B, Decker C, Markowitz M, Carter E, Bobbitt W, Dahdul A, DeCastro E, et al: Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2002, 97 (12): 3139-3146. 10.1111/j.1572-0241.2002.07111.x.
Article
CAS
PubMed
Google Scholar
Chilton F, Collett RA: Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008, 6 (1): 1-14. 10.1002/msc.110.
Article
PubMed
Google Scholar
Williams EL, Edwards CJ: Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford). 2006, 45 (12): 1575-1576. 10.1093/rheumatology/kel369.
Article
CAS
Google Scholar
Oussalah A, Babouri A, Chevaux J-B, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard M-A, Peyrin-Biroulet L: Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Alimentary Pharmacology & Therapeutics. 2009, 29 (4): 416-423. 10.1111/j.1365-2036.2008.03902.x.
Article
CAS
Google Scholar
Love JR, Irvine EJ, Fedorak RN: Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992, 14 (1): 15-19. 10.1097/00004836-199201000-00005.
Article
CAS
PubMed
Google Scholar
Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C: A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989, 96 (3): 804-810.
Article
CAS
PubMed
Google Scholar
Ananthakrishnan AN, Weber LR, Knox JF, Skaros S, Emmons J, Lundeen S, Issa M, Otterson MF, Binion DG: Permanent work disability in Crohn's disease. Am J Gastroenterol. 2008, 103 (1): 154-161. 10.1111/j.1572-0241.2008.02054.x.
Article
PubMed
Google Scholar
Deber RB: Shared decision making in the real world. J Gen Intern Med. 1996, 11 (6): 377-378. 10.1007/BF02600052.
Article
CAS
PubMed
Google Scholar
Bodger K, Kikuchi T, Hughes D: Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009, 30 (3): 265-274. 10.1111/j.1365-2036.2009.04033.x.
Article
CAS
PubMed
Google Scholar